115 related articles for article (PubMed ID: 34589619)
1. Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation.
Smith CW; Alfano R; Hoover D; Surry K; D'Souza D; Thiessen J; Rachinsky I; Butler J; Gomez JA; Gaed M; Moussa M; Chin J; Pautler S; Bauman GS; Ward AD
Phys Imaging Radiat Oncol; 2021 Jul; 19():102-107. PubMed ID: 34589619
[TBL] [Abstract][Full Text] [Related]
2. Viability of focal dose escalation to prostate cancer intraprostatic lesions using HDR prostate brachytherapy.
Poder J; Radvan S; Howie A; Kasraei F; Parker A; Bucci J; Haworth A
Brachytherapy; 2023; 22(6):800-807. PubMed ID: 37748989
[TBL] [Abstract][Full Text] [Related]
3. A multiobserver study investigating the effectiveness of prostatic multiparametric magnetic resonance imaging to dose escalate corresponding histologic lesions using high-dose-rate brachytherapy.
Smith CW; Hoover D; Surry K; D'Souza D; Cool DW; Kassam Z; Bastian-Jordan M; Gomez JA; Moussa M; Chin J; Pautler S; Bauman GS; Ward AD
Brachytherapy; 2021; 20(3):601-610. PubMed ID: 33648893
[TBL] [Abstract][Full Text] [Related]
4. Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology.
Smith CW; Marcus T; Hoover D; Surry K; D'Souza D; Cool D; Kassam Z; Bastian-Jordan M; Gómez JA; Moussa M; Chin JL; Pautler S; Bauman GS; Ward AD
Brachytherapy; 2022; 21(4):435-441. PubMed ID: 35337747
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts.
Goodman CD; Fakir H; Pautler S; Chin J; Bauman GS
Adv Radiat Oncol; 2020; 5(2):212-220. PubMed ID: 32280821
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
8. Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer.
Holzschuh JC; Mix M; Ruf J; Hölscher T; Kotzerke J; Vrachimis A; Doolan P; Ilhan H; Marinescu IM; Spohn SKB; Fechter T; Kuhn D; Bronsert P; Gratzke C; Grosu R; Kamran SC; Heidari P; Ng TSC; Könik A; Grosu AL; Zamboglou C
Radiother Oncol; 2023 Nov; 188():109774. PubMed ID: 37394103
[TBL] [Abstract][Full Text] [Related]
9. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
10. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
[TBL] [Abstract][Full Text] [Related]
11. Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network.
Kostyszyn D; Fechter T; Bartl N; Grosu AL; Gratzke C; Sigle A; Mix M; Ruf J; Fassbender TF; Kiefer S; Bettermann AS; Nicolay NH; Spohn S; Kramer MU; Bronsert P; Guo H; Qiu X; Wang F; Henkenberens C; Werner RA; Baltas D; Meyer PT; Derlin T; Chen M; Zamboglou C
J Nucl Med; 2021 Jun; 62(6):823-828. PubMed ID: 33127624
[TBL] [Abstract][Full Text] [Related]
12. PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01).
Zamboglou C; Spohn SKB; Ruf J; Benndorf M; Gainey M; Kamps M; Jilg C; Gratzke C; Adebahr S; Schmidtmayer-Zamboglou B; Mix M; Bamberg F; Zschaeck S; Ghadjar P; Baltas D; Grosu AL
Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1025-1035. PubMed ID: 35469897
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
14. [
Bettermann AS; Zamboglou C; Kiefer S; Jilg CA; Spohn S; Kranz-Rudolph J; Fassbender TF; Bronsert P; Nicolay NH; Gratzke C; Bock M; Ruf J; Benndorf M; Grosu AL
Radiother Oncol; 2019 Dec; 141():214-219. PubMed ID: 31431366
[TBL] [Abstract][Full Text] [Related]
15. Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary?
Kovács G; Galalae R
Cancer Radiother; 2003 Apr; 7(2):100-6. PubMed ID: 12719039
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer GTV delineation with biparametric MRI and
Hearn N; Blazak J; Vivian P; Vignarajah D; Cahill K; Atwell D; Lagopoulos J; Min M
Br J Radiol; 2021 Mar; 94(1119):20201174. PubMed ID: 33507812
[TBL] [Abstract][Full Text] [Related]
17. Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer.
Zamboglou C; Rischke HC; Meyer PT; Knobe S; Volgeova-Neher N; Kollefrath M; Jilg CA; Grosu AL; Baltas D; Kroenig M
J Contemp Brachytherapy; 2016 Jun; 8(3):241-8. PubMed ID: 27504134
[TBL] [Abstract][Full Text] [Related]
18. Histologic validation of auto-contoured dominant intraprostatic lesions on [
Alfano R; Bauman GS; Liu W; Thiessen JD; Rachinsky I; Pavlosky W; Butler J; Gaed M; Moussa M; Gomez JA; Chin JL; Pautler S; Ward AD
Radiother Oncol; 2020 Nov; 152():34-41. PubMed ID: 32827589
[TBL] [Abstract][Full Text] [Related]
19. Pilot study comparing dominant intraprostatic lesion volume using Ga-68 prostate-specific membrane antigen PET-computed tomography and multiparametric MRI.
Sasidharan A; Murthy V; Natarajan A; Agarwal A; Ranagrajan V; Gudi S; Singh S; Popat P
Nucl Med Commun; 2020 Dec; 41(12):1291-1298. PubMed ID: 32941400
[TBL] [Abstract][Full Text] [Related]
20. Spatial Pattern of Intraprostatic Recurrence after Definitive External-Beam Radiation Therapy for Prostate Cancer: Implications for Focal Boost to Intraprostatic Dominant Lesion.
Aizawa R; Otani T; Ogata T; Moribata Y; Kido A; Akamatsu S; Goto T; Masui K; Sumiyoshi T; Kita Y; Kobayashi T; Nakamoto Y; Mizowaki T
Adv Radiat Oncol; 2024 Jun; 9(6):101489. PubMed ID: 38681892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
